WDB coco Co., Ltd. (TYO:7079)
2,568.00
+8.00 (0.31%)
May 28, 2026, 3:30 PM JST
WDB coco Revenue
In the fiscal year ending March 31, 2026, WDB coco had annual revenue of 4.82B JPY, down -9.59%. WDB coco had revenue of 1.18B in the quarter ending March 31, 2026, a decrease of -11.91%.
Revenue
4.82B
Revenue Growth
-9.59%
P/S Ratio
1.28
Revenue / Employee
8.51M
Employees
566
Market Cap
6.18B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 4.82B | -511.00M | -9.59% |
| Mar 31, 2025 | 5.33B | 731.00M | 15.91% |
| Mar 31, 2024 | 4.60B | 525.00M | 12.90% |
| Mar 31, 2023 | 4.07B | 455.00M | 12.59% |
| Mar 31, 2022 | 3.62B | 1.05B | 40.66% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharma Foods International | 67.84B |
| Fuso Pharmaceutical Industries,Ltd. | 62.17B |
| Nippon Chemiphar | 33.09B |
| Morishita Jintan | 12.69B |
| Wakamoto Pharmaceutical | 9.43B |
| Taiko Pharmaceutical | 6.16B |
| SymBio Pharmaceuticals | 1.28B |
| Solasia Pharma K.K. | 410.00M |